Gilead Sciences’ closely-watched hepatitis C drug Sovaldi has been given the green light in Europe.
The European Commission has granted marketing authorisation for Sovaldi (sofosbuvir) 400mg tablets
which, as part of HCV combination therapy with peg-interferon and ribavirin, offers cure rates of around 90% in previously-untreated adults. However, most significant is that the once-daily nucleotide analogue polymerase inhibitor is the first all-oral treatment option for up to 24 weeks for patients unsuitable for interferon.
Read more at: http://www.pharmatimes.com/Article/14-01-20/Gilead_s_HCV_drug_Sovaldi_gets_Europe_OK.aspx#ixzz2qwHI3iJi
SYNTHESIS
-
sofosbuvir » All About Drugs
http://www.allfordrugs.com/tag/sofosbuvir/ALL ABOUT DRUGS BY DR ANTHONY MELVIN CRASTO, WORLD DRUG TRACKER HELPING … US Approves Breakthrough Hepatitis C Drug,Sofosbuvir.
Filed under: EU PIPELINE Tagged: drug, Europe, Gilead, HCV, OK, Sofosbuvir, Sovaldi
